Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
IPH2201 · 1 trial · 1 indication
To confirm the recommended phase II dose (RP2D) of single agent IPH2201 in patients with advanced/metastatic/recurrent platinum sensitive or resistant high-grade serous carcinoma (HGSC) of ovarian, fallopian tube or peritoneal origin.
| Arm | Type | Description |
|---|---|---|
| IPH2201 | EXPERIMENTAL | Part 1: 1, 4 or 10mg/kg, IV, 1 hour duration on Day 1 every 2 weeks. Part 2: Patients will receive single agent IPH2201 as above with the actual dose dependent on the outcome of Part 1 |
| Name | Type | Description |
|---|---|---|
| IPH2201 | DRUG | - |
Inclusion Criteria: * Patients must have a histologically and/or cytologically confirmed gynecologic malignancy including high-grade serous ovarian/fallopian tube or peritoneal carcinoma, cervical cancer (squamous cell carcinoma) or endometrial cancer (adenocarcinoma), that is advanced/metastatic/r...
IPH2201 is an investigational small molecule being studied for the treatment of gynecologic cancer. It is in Phase 1 clinical development and is not yet approved by regulatory authorities.
IPH2201 is being developed by Innate Pharma S.A., a biopharmaceutical company listed on the stock exchange under the ticker symbol IPHA.
IPH2201 is in Phase 1 clinical development. It is an investigational drug and has not been approved for any use. One Phase 1 trial has been completed.
IPH2201 has been studied in a completed Phase 1 trial with the identifier NCT02459301. This was a dose-ranging study in patients with gynecologic malignancies, conducted in Canada with 59 female participants aged 18 years and older.
IPH2201 is being studied in a biomarker-selected patient population, indicating that its development involves the use of biomarkers to identify patients who may be more likely to respond to treatment.